New data on berotralstat to be shared at 2025 meeting of the European Academy of Allergy and Clinical Immunology
New data on the use of berotralstat (Orladeyo) for the prevention of HAE attacks will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) meeting, according to an announcement shared by the pharmaceutical company BioCryst.
Four abstracts will be presented at the meeting:
- Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials
- Patients with HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group
- Assessment of the Effectiveness and Tolerability of Berotralstat for Long-term Prophylaxis in Hereditary Angioedema: Findings from the Berolife Study
- Berotralstat Use Reduced Number of HAE Attacks Requiring Treatment or Professional Care in Pediatric Patients: Interim Results from APeX-P
The EAACI meeting will take place in in Glasgow, United Kingdom, from 13-16 June 2025.
(Source: BioCryst)